Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection.

Bhavsar, Disha; Singh, Gagandeep; Sano, Kaori; Gleason, Charles; Srivastava, Komal; Carreno, Juan Manuel; Simon, Viviana; Krammer, Florian.

Afiliação

Bhavsar D; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Singh G; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Sano K; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Gleason C; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Srivastava K; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Carreno JM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Simon V; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

mBio ; : e0228023, 2023 Dec 01.

Article em En | MEDLINE | ID: mdl-38092666

ABSTRACT

IMPORTANCE Antibodies on mucosal surfaces of the upper respiratory tract have been shown to be important for protection from infection with SARS-CoV-2. Here we investigate the induction of serum IgG, saliva IgG, and saliva sIgA after COVID-19 mRNA booster vaccination or breakthrough infections.

Palavras-chave

SARS-CoV-2; booster vaccination; breakthrough infection; mRNA vaccine; sIgA; saliva; spike

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article